Nils Lonberg

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and platform development teams in the biotech and pharma industry for the last 30 years, most recently as Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb. Prior to that he was Scientific Director at Genpharm International and Medarex, where his research groups developed genetically engineered strains of mice with human immunoglobulin genes that have been used to discover 10 FDA-approved antibody therapeutics, including ipilimumab and nivolumab, two drugs discovered by Dr. Lonberg’s team that target immune-attenuating pathways to activate patient immune responses to multiple cancers (so-called "checkpoint blockade" therapies). Dr. Lonberg received his PhD in Biochemistry and Molecular Biology from Harvard University (Cambridge, MA) in 1985, and was elected to the National Academy of Engineering in 2015.